The BRCA1 and BRCA2 genes are crucial actors in the DNA damage response and repair pathway; a function that is critical in preserving the integrity of the genome. Mutations that meddle with the nor...
Published in the Journal of Clinical Oncology, the study has potential implications for families with members suffering from these two types of tumours who are at an increased risk of developing cance...
The IDMC's recommendation came after an analysis of the safety data obtained with the first 80 patients treated in the trial. This pivotal randomised Phase III trial assesses the efficacy of PM1183 co...
Myriad is actively collaborating with leading pharmaceutical companies to develop Tumor BRACAnalysis CDx as a companion diagnostic for use with certain PARP inhibitors, platinum-based drugs and other ...
Lynparza is the first poly ADP-ribose polymerase (PARP) inhibitor for patients with germline mutations in BRCA1/2 advanced ovarian cancer who have had three or more lines of chemotherapy
PharmaMar´s antitumor agent PM1183 significantly improves overall survival compared with standard therapy in patients with resistant/refractory ovarian cancer